According
to the study According to the study, ‘Fungal Foot Infections Drug Development Pipeline
Review, 2018’, The
global athlete’s foot treatment market can be segmented based on drug
class, route of administration, distribution channel, and region. Based on
the drug intake, the entire industry can be divided into oral and topical
antifungals. The sale of these drugs takes place via online pharmacies,
hospitals and retail pharmacies. The two main divisions in terms of class of
drugs are antifungal antibiotics and steroids and some others.
Foot infections of both the skin and nails of the feet
are caused by fungi, virus as well as bacteria. Only in case of fungal
infection is it visible since virus and bacteria are invisible to the human
eye. Fungi are present everywhere in our day to day surroundings. They flourish
mostly in dark moist environments attacking the skin and nails of feet
especially when the skin is ragged, making it susceptible to invasion. The most
typical form of fungal infection is athlete’s foot or Tinea Pedis, its medical name.
Athlete’s
foot most commonly affects the skin between the toes or on the bottom of the
feet; causing itching, redness and peeling and sometimes a burning sensation as
well as blisters. If untreated, the infection can spread to the toenails
leading to the Infection of the nails is called onychomycosis (Tinea
Unguium).
Onychomycosis can cause
pain, discomfort, and disfigurement and may produce serious physical and
occupational limitations, as well as reducing quality of life. The
most common test for identifying athlete’s foot is the potassium hydroxide
(KOH) exam. A doctor scrapes off a small
area of infected skin and places it in potassium hydroxide (KOH). The KOH
destroys normal cells and leaves the fungal cells untouched so they are easy to
see under a microscope.
The treatment of this disease depends
upon tree drug classes namely, the azoles (e.g. flucanzole, the echinocandins
and amphotericin to cure these diseases. However, these drugs result in limited
success. To identify new drugs and antifungals, a team of Whitehead and
MIT scientists recently screened nearly
3000,000 compounds and found INZ -1 to be have the most apparent potential. In
2016, Blueberry Therapeutics raised EUR 3 Million to innovate and research in
drug for topical fungal infection therapies and to move them to clinical
trials. The investment will lead into development of possible effect cures for
onychomycosis and tinea pedis. In humongous market patients have wanted a drug
that has the efficiency of oral treatment but without the threats associated
with level of toxicity.
Key
players operating in the global athlete’s foot (tinea pedis) treatment market
are Valeant Pharmaceuticals, Quinnova Pharmaceuticals, Inc., Anacor
Pharmaceuticals, Inc., Cardinal Health, Novartis AG, Merck & Co, Inc.,
Bayer Healthcare LLC, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Medimetriks
Pharmaceuticals, Inc., Medicis Pharmaceutical Corporation, and Johnson and
Johnson Healthcare.
Recent
developments have proven that fungal infections can be cured in a much quicker
and efficient manner with least side effects. Huge investments are being made
by companies and investment firms to further expand the scope of the research. The
fungal foot infection drug development market will grow at an exponential rate.
To know more, click on the link
below:
Related Report:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91-9015378249
